(Q36390870)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

review article

1 reference

title

Dopamine agonists in the treatment of Parkinson's disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

author name string

Nicola Pavese

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

publication date

1 January 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

16 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

page(s)

81-89

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

Pathogenetic mechanisms of parkin in Parkinson's disease

16 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Stages in the development of Parkinson's disease-related pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pramipexole--a new dopamine agonist for the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Choosing dopamine agonists in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Bromocriptine and levodopa (with or without carbidopa) in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Bromocriptine in Parkinson disease: Further studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Switching from pergolide to pramipexole in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Dual dopamine agonist treatment in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Literature review: intermittent subcutaneous apomorphine therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Levodopa and the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pharmacology of dopamine agonists in the treatment of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

A novel mechanism for pergolide-induced neuroprotection: inhibition of NF-kappaB nuclear translocation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Prospects for the treatment of Parkinson's disease using neurotrophic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Apomorphine up-regulates NGF and GDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Effects of dopamine agonists bromocriptine, pergolide, cabergoline, and SKF-38393 on GDNF, NGF, and BDNF synthesis in cultured mouse astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Cabergoline stimulates synthesis and secretion of nerve growth factor, brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor by mouse astrocytes in primary culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Involvement of dopamine D(2)/D(3) receptors and BDNF in the neuroprotective effects of S32504 and pramipexole against 1-methyl-4-phenylpyridinium in terminally differentiated SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Imaging end points for monitoring neuroprotection in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

A comparison of the progression of early Parkinson's disease in patients started on ropinirole or L-dopa: an 18F-dopa PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Excessive Daytime Sleepiness and Sudden-Onset Sleep in Parkinson Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Excessive daytime sleepiness in parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Sleep episodes in Parkinson's disease: a wake-up call.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Dopamine agonists and sleep in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Sleep attacks in patients taking dopamine agonists: review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Predictors of sudden onset of sleep in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Sudden uncontrollable somnolence and medication use in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Fibrosis associated with dopamine agonist therapy in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.6.1.81

21 January 2018

Identifiers

DOI

10.1586/14737175.6.1.81

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16466315%20AND%20SRC:MED&resulttype=core&format=json

16 January 2020

1 reference